Ozempic and Wegovy maker Novo Nordisk now worth $500B amid soaring popularity

The soaring popularity of weight loss drugs Ozempic and Wegovy has catapulted parent company Novo Nordisk’s valuation past the half-trillion dollar threshold, according to a report.The Danish pharmaceutical company, which initially marketed the drugs as a treatment for diabetes, has a valuation of $506 billion, according to CNBC, which analyzed data from the London Stock Exchange Group.Novo Nordisk’s stock price was up by nearly 5$114, after the company released better-than-expected quarterly ...